Welcome to Dispensed, Business Insider's weekly newsletter giving you a dose of pharma, biotech, and healthcare news.
OK show of hands, how many of you have finally hit your limit on Theranos/Elizabeth Holmes content? I think across the newsroom, we pulled togetherin the last week and a half . I'd definitely recommend checking them all out if you can't get enough of the story. Up next in the saga: awaiting the trial. There's a court date scheduled for late April, I'll be sure to keep you posted as the trial starts to get underway.
Two months ago, Apple CEO Tim Cook said his company's"greatest contribution to mankind" would be in health. OK, I know I said we were almost done chatting about Theranos until the trial gets underway, but I couldn't help slipping one more interview I posted this week — this one with Dr. Phyllis Gardner, a professor at Stanford who shot down one of Elizabeth Holmes' early ideas and watched as the entire rise and fall of the company unfolded. Favorite quotes include:"I was just barfing all over the place.
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
The Stanford professor who rejected one of Elizabeth Holmes’s early ideas explains what it was like to watch the rise and fall of TheranosDr. Phyllis Gardner was one of the earliest skeptics of Theranos founder Elizabeth Holmes. 'I just want her convicted,' Gardner now says.
Lire la suite »
Regulators just approved a new depression drug with the potential to be a game-changerUnlike the depression drugs available for decades, neither of the two new drugs is a pill. One is a nasal spray; the latest is an injection made by Sage.
Lire la suite »
A new drug based on ketamine could help treat depressionMost antidepressants take weeks or months to take effect. A ketamine-based drug takes only hours
Lire la suite »
Ichiro says goodbye to adoring fans; Mariners beat A's in 12Ichiro Suzuki was showered with cheers and chants Thursday night while taking his final bow in a magnificent career that lasted nearly three decades when the Seattle Mariners beat the Oakland Athletics 5-4 in 12 innings. The 45-year-old Ichiro went 0 for 4 in the second game of the Major...
Lire la suite »
Biogen scraps two Alzheimer drug trials, wipes $18 billion from market valueBiogen Inc and partner Eisai Co Ltd are ending two late-stage trials of their ex...
Lire la suite »
Biogen heads for the worst day in a decade after ending trial for blockbuster Alzheimer's drugShares of Biogen plummeted Thursday after the company halted the trial of Alzheimer's disease drug aducanumab.
Lire la suite »
Biogen scraps Alzheimer drug trials, wiping $17 billion off its market valueReuters - Biogen and partner Eisai Co Ltd are ending two late-stage trials for t...
Lire la suite »
Biogen scraps Alzheimer drug trials, shares slump by a quarterBiogen and partner Eisai Co Ltd are ending two late-stage trials testing the exp...
Lire la suite »
Eisai starts phase 3 trials for second Alzheimer's drug after first's failureEisai Co Ltd on Friday said it has begun phase 3 clinical trials of Alzheimer&0...
Lire la suite »
How Will The Failure Of Biogen's Alzheimer's Drug, Aducanumab, Impact R&D?The death of an important drug like aducanumab will have both a short and a long term effect on Biogen as a company and especially on R&D.
Lire la suite »